<DOC>
	<DOCNO>NCT01951235</DOCNO>
	<brief_summary>This study ass efficacy safety/tolerability 4 dos Imeglimin versus placebo . The study perform subject type 2 diabetes either naive treatment previously treat oral monotherapy exclude thiazolidinedione .</brief_summary>
	<brief_title>A Study Efficacy Safety 4 Doses Imeglimin After 24 Weeks Treatment Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>1 . Subject give write informed consent 2 . Male female type 2 diabetic subject , either naïve antidiabetic agent treat oral antidiabetic monotherapy . 3 . Body mass index ( BMI ) : ≥ 24 ≤ 40 kg/m² 4 . HbA1c criterion : ≥ 7 % ≤ 9.5 % 5 . Creatinine clearance ≥ 50 mL/ [ min*1.73 m2 ] Screening Visit 6 . Effective contraception woman child bear potential 1 . Any disease investigator 's opinion would exclude subject study 2 . Acute cardiovascular event within 3 month randomization 3 . Uncontrolled high blood pressure 4 . Impairment hepatic function 5 . History druginduced Torsades de Pointes mark baseline prolongation QTc interval 6 . Pregnancy lactation 7 . Use nonpermitted medication 8 . Positive screen viral hepatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>